For those looking to cite research papers on the FIRMM software by NOUS Imaging, please use the following references (via Science Direct).
For more information, email info@firmm.io or contact us.
Dr. Fair is a prominent cognitive neuroscientist and MRI researcher. He will be taking over the Directorship of the newly formed, freestanding Institute of Child and Adolescent Brain Health at the University of Minnesota in July of 2020. Dr. Fair obtained his PhD in Neuroscience at Washington University, where he met co-founder, Dr. Dosenbach.
Mr. Miller is Chairman of the Board at NOUS Imaging and provides strategic planning and product marketing guidance. He has extensive early stage management experience in the MR imaging industry and has led multiple worldwide medical imaging product launches. Mr. Miller is currently CEO, President and a member of the Board of Directors of Nortech Systems, Inc. (Maple Grove, MN). Mr. Miller has extensive technical and managerial experience in the medical imaging & device industry. Previously, Mr. Miller was the President and CEO of IMRIS, Inc. (MR- and CT-guided neurosurgery), President & CEO of Zonare Medical Systems, Inc. (ultrasound), President & CEO of Vital Images, Inc. (advanced visualization of CT & MR), and held senior roles in the MR businesses at GE Medical Systems (now GE Healthcare) and Siemens Healthcare (now Siemens Healthineers).
Mr. Kokke is Chief Investment Officer (CIO) of CICA, Inc., a California based investment advisory firm specializing in alternative assets such as Real Estate, Private Equity and Hedge Funds. CICA Inc. Private Equity has a strong focus on biotech, med-tech and other healthcare fields, with 29 seed investments lead by Mr. Kokke. Prior to becoming CIO, he served in various positions at CICA, Inc.
Mr. Schoepflin is active as a venture capitalist in the United States, Europe and Asia. He is a former Director and seed investor in The Price Company, now known as Costco (founder and creator of the retail warehouse industry), as well as in numerous other companies. Prior to his involvement in The Price Company, Mr. Schoepflin was President and Chief Executive Officer of The FedMart Corporation. He also was involved in the initial seed financing of QUALCOMM Corporation and has been a significant early stage and seed investor in biotech and medical technologies companies. He was a seed investor in Actelion Pharmaceuticals in 1997 which sold to Johnson and Johnson in 2017.
Ken Bruener currently serves as President and CEO of NOUS Imaging and is a member of the Board of Directors. Ken is an experienced executive and leader in the medical technology space. During his 24-year career he has worked in commercialization, marketing, business development and general management roles in the areas of neuro, spine, orthopedics, surgery and digital health. Prior to joining NOUS, Ken was President and a member of the Board of Directors at Jan Medical where he worked closely with key leaders from across the spectrum of healthcare and athletics. Ken was also previously the Vice President of Global Business Development as well as VP of Marketing at Brainlab AG. Before joining Brainlab, Ken held roles of increasing responsibility in sales management, marketing and business development at Codman, a Johnson and Johnson Company and Kinetic Concepts. Ken has spent his entire 24-year professional career in the medical industry and holds bachelor’s degrees in marketing and economics and an MBA from The University of Florida.
Dr. Dosenbach is a pediatric neurologist and systems neuroscientist, running a neuroimaging research laboratory in the Mallinckrodt Institute of Radiology at Washington University School of Medicine. Dr. Dosenbach sees patients at St. Louis Children’s Hospital. Dr. Dosenbach obtained his MD and PhD at Washington University and has been collaborating closely with Dr. Fair for 15 years.
Dr. McCann is on the Board of Directors of NOUS imaging. He is currently the President and CEO of Pear Therapeutics, a company that develops clinically-validated software-based therapeutics or Prescription Digital Therapeutics (PTD). Prior to his role in Pear Therapeutics, Dr. McCann worked with a number of investment firms, including MPM Capital, McKinsey & Company, and RiverVest Venture Partners, to evaluate and manage novel healthcare technology companies. Dr. McCann received his PhD training from Harvard University and Washington University in St. Louis and completed his MD at Washington University in St. Louis. He later went on to complete his post-doctoral training at Massachusetts General Hospital prior to starting his career.
